-
★
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
(Hinzugefügt: 20.06.2021 um 10:43 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2101643
-
★
COVID-19 therapeutics tracker
(Hinzugefügt: 08.03.2021 um 09:20 Uhr)
https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker
-
Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin
(Hinzugefügt: 25.11.2021 um 19:19 Uhr)
https://www.tandfonline.com/doi/full/10.1080/21505594.2021.2006960
-
BPC 157 as Potential Treatment for COVID-19
(Hinzugefügt: 20.11.2021 um 11:05 Uhr)
https://www.sciencedirect.com/science/article/pii/S0306987721002553
-
Metformin Suppresses SARS-CoV-2 in Cell Culture
(Hinzugefügt: 20.11.2021 um 10:28 Uhr)
https://www.biorxiv.org/content/10.1101/2021.11.18.469078v1
-
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial
(Hinzugefügt: 19.11.2021 um 21:06 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00315-5/fulltext
-
A new treatment for diabetic foot ulcers could also be used to eradicate the COVID-19 virus.
(Hinzugefügt: 19.11.2021 um 15:49 Uhr)
http://newalert.mengawasi.com/2021/11/a-new-treatment-for-diabetic-foot.html
-
Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro
(Hinzugefügt: 19.11.2021 um 15:41 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.08.415505v2
-
COVID-19: Auch Fluoxetin könnte vor schweren Verläufen schützen
(Hinzugefügt: 19.11.2021 um 15:38 Uhr)
https://www.aerzteblatt.de/nachrichten/129126/COVID-19-Auch-Fluoxetin-koennte-vor-schweren-Verlaeufen-schuetzen
-
Neue Therapie-Option bei schwerer Covid-19-Erkrankung
(Hinzugefügt: 19.11.2021 um 15:19 Uhr)
https://www.meduniwien.ac.at/web/ueber-uns/news/news-im-april-2021/neue-therapie-option-bei-schwerer-covid-19-erkrankung/
-
A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
(Hinzugefügt: 15.11.2021 um 07:38 Uhr)
https://rupress.org/jem/article/219/1/e20211818/212765/A-stem-loop-RNA-RIG-I-agonist-protects-against
-
Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19
(Hinzugefügt: 09.11.2021 um 15:54 Uhr)
https://insight.jci.org/articles/view/148749
-
Statins use and COVID-19 outcomes in hospitalized patients
(Hinzugefügt: 04.11.2021 um 09:17 Uhr)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0256899
-
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
(Hinzugefügt: 04.11.2021 um 08:46 Uhr)
https://www.science.org/doi/10.1126/science.abl4784
-
Camel nanobodies broadly neutralize SARS-CoV-2 variants
(Hinzugefügt: 01.11.2021 um 10:05 Uhr)
https://www.biorxiv.org/content/10.1101/2021.10.27.465996v1
-
U of T researchers create mirror-image peptides that can neutralize SARS-CoV-2
(Hinzugefügt: 29.10.2021 um 13:39 Uhr)
https://www.utoronto.ca/news/u-t-researchers-create-mirror-image-peptides-can-neutralize-sars-cov-2
-
Is butyrate a natural alternative to dexamethasone in the management of CoVID-19?
(Hinzugefügt: 25.10.2021 um 07:35 Uhr)
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8108555/
-
A prenylated dsRNA sensor protects against severe COVID-19
(Hinzugefügt: 29.09.2021 um 10:11 Uhr)
https://www.science.org/doi/10.1126/science.abj3624
-
5-Hydroxymethyltubercidin Exhibits Potent Antiviral Activity against Flaviviruses and Coronaviruses, including SARS-CoV-2
(Hinzugefügt: 20.09.2021 um 09:24 Uhr)
https://www.cell.com/iscience/fulltext/S2589-0042(21)01088-9
-
Nature-Studie zur Seneszenz eröffnet neuen Therapieansatz
(Hinzugefügt: 15.09.2021 um 16:08 Uhr)
https://www.charite.de/service/pressemitteilung/artikel/detail/covid_19_was_die_lawine_der_entzuendung_antreibt/
-
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
(Hinzugefügt: 15.09.2021 um 15:47 Uhr)
https://www.sciencedirect.com/science/article/pii/S2589004221010087
-
Fostamatinib for the treatment of hospitalized adults with COVID-19 A randomized trial
(Hinzugefügt: 15.09.2021 um 15:14 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab732/6358811
-
A Randomized Trial of Icosapent Ethyl in Ambulatory Patients with COVID-19
(Hinzugefügt: 28.08.2021 um 13:39 Uhr)
https://www.sciencedirect.com/science/article/pii/S2589004221010087
-
Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial
(Hinzugefügt: 26.08.2021 um 04:32 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.19.21262323v1
-
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
(Hinzugefügt: 26.08.2021 um 04:19 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00216-2/fulltext
-
Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer
(Hinzugefügt: 26.08.2021 um 04:10 Uhr)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2783284
-
Long-Covid: Erlanger Mediziner melden Erfolge mit Herzmedikament
(Hinzugefügt: 26.08.2021 um 04:01 Uhr)
https://www.br.de/nachrichten/bayern/long-covid-erlanger-mediziner-melden-erfolge-mit-herzmedikament,Sh5kEXH?fbclid=IwAR0fR_V3y0HgATc5d2fbwuzMMHoLNa0MDS9ScMnoKgMjk9W_KnNZqYuMTWs
-
A licensed drug normally used to treat abnormal levels of fatty substances in the blood could reduce infection caused by the SARS-CoV-2 virus by up to 70 per cent, reveals a study in the laboratory by an international collaboration of researchers.
(Hinzugefügt: 24.08.2021 um 17:20 Uhr)
https://www.birmingham.ac.uk/news/latest/2021/08/covid-licensed-drug-reduce-infection.aspx
-
Antidepressant fluvoxamine can save COVID-19 patients, McMaster-led research shows
(Hinzugefügt: 24.08.2021 um 16:33 Uhr)
https://brighterworld.mcmaster.ca/articles/antidepressant-fluvoxamine-can-save-covid-19-patients-mcmaster-led-research-shows/
-
Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.
(Hinzugefügt: 24.08.2021 um 15:08 Uhr)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00261-3/fulltext
-
Therapeutic Solutions International Prepares to Apply for Emergency Use Authorization (EUA) for its FDA Phase III COVID-19 Stem Cell Therapy JadiCell™
(Hinzugefügt: 24.08.2021 um 15:07 Uhr)
https://therapeuticsolutionsint.com/therapeutic-solutions-international-prepares-to-apply-for-emergency-use-authorization-eua-for-its-fda-phase-iii-covid-19-stem-cell-therapy-jadicell/
-
Krebsmedikament reduziert in kleiner Studie Mortalität bei COVID-19-bedingtem Lungenversagen
(Hinzugefügt: 14.08.2021 um 08:37 Uhr)
https://www.aerzteblatt.de/nachrichten/126353/Krebsmedikament-reduziert-in-kleiner-Studie-Mortalitaet-bei-COVID-19-bedingtem-Lungenversagen
-
Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection
(Hinzugefügt: 03.08.2021 um 10:12 Uhr)
https://pubmed.ncbi.nlm.nih.gov/34214498/
-
Interferon-inducer antivirals: Potential candidates to combat COVID-19
(Hinzugefügt: 03.08.2021 um 09:23 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705326/pdf/main.pdf
-
Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide
(Hinzugefügt: 27.07.2021 um 19:23 Uhr)
https://www.medrxiv.org/content/10.1101/2021.07.24.21261047v1
-
Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide
(Hinzugefügt: 27.07.2021 um 19:23 Uhr)
https://www.medrxiv.org/content/10.1101/2021.07.24.21261047v1
-
Programmable icosahedral shell system for virus trapping
(Hinzugefügt: 19.07.2021 um 11:45 Uhr)
https://www.nature.com/articles/s41563-021-01020-4
-
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
(Hinzugefügt: 17.07.2021 um 13:39 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00263-0/fulltext?utm_campaign=lancetcovid21&utm_content=172627854&utm_medium=social&utm_source=facebook&hss_channel=fbp-374651963469
-
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
(Hinzugefügt: 17.07.2021 um 13:13 Uhr)
https://en.kintor.com.cn/news/183.html
-
Gen-Schere kann Coronavirus stoppen
(Hinzugefügt: 14.07.2021 um 10:02 Uhr)
https://www.n-tv.de/wissen/Gen-Schere-kann-Coronavirus-stoppen-article22679478.html
-
WHO recommends Roche, Sanofi drugs for COVID-19 to cut death risk
(Hinzugefügt: 09.07.2021 um 18:54 Uhr)
https://www.ctvnews.ca/health/coronavirus/who-recommends-roche-sanofi-drugs-for-covid-19-to-cut-death-risk-1.5498704
-
Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients
(Hinzugefügt: 09.07.2021 um 18:47 Uhr)
https://www.sciencedirect.com/science/article/pii/S2052297521000792
-
WHO empfiehlt IL-6-Antagonisten bei COVID-19
(Hinzugefügt: 09.07.2021 um 18:40 Uhr)
https://www.aerzteblatt.de/nachrichten/125369/WHO-empfiehlt-IL-6-Antagonisten-bei-COVID-19
-
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
(Hinzugefügt: 09.07.2021 um 18:40 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2781880
-
Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study
(Hinzugefügt: 07.07.2021 um 07:16 Uhr)
https://pubmed.ncbi.nlm.nih.gov/34135619/
-
NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI™ (Aviptadil) Expanded Access Protocol
(Hinzugefügt: 23.06.2021 um 18:11 Uhr)
https://ir.nrxpharma.com/news-events/press-releases/detail/70/nrx-pharmaceuticals-announces-positive-data-results-from
-
Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease
(Hinzugefügt: 23.06.2021 um 18:07 Uhr)
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(21)00286-9
-
Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
(Hinzugefügt: 23.06.2021 um 18:06 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33633920/
-
Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial
(Hinzugefügt: 23.06.2021 um 18:05 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.22.21259318v1
-
Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial
(Hinzugefügt: 23.06.2021 um 18:05 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.22.21259318v1
-
A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection
(Hinzugefügt: 23.06.2021 um 18:05 Uhr)
https://immunology.sciencemag.org/content/6/59/eabi9002.full
-
Studie: Krebsmedikament Imatinib könnte Mortalität von COVID-19-Patienten senken
(Hinzugefügt: 23.06.2021 um 18:02 Uhr)
https://www.aerzteblatt.de/nachrichten/124897/Studie-Krebsmedikament-Imatinib-koennte-Mortalitaet-von-COVID-19-Patienten-senken
-
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial
(Hinzugefügt: 23.06.2021 um 18:02 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00237-X/fulltext
-
Neuer Therapieansatz? Bandwurmmittel senkt Sars-CoV-2-Produktion in Zellen um über 99 Prozent
(Hinzugefügt: 22.06.2021 um 07:20 Uhr)
https://www.rnd.de/gesundheit/bandwurmmittel-senkt-sars-cov-2-produktion-in-zellen-um-ueber-99-prozent-GMFOAL4Q2JHVZGN3MD6QYVH3IY.html
-
NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI™ (Aviptadil) Expanded Access Protocol
(Hinzugefügt: 20.06.2021 um 17:47 Uhr)
https://ir.nrxpharma.com/news-events/press-releases/detail/70/nrx-pharmaceuticals-announces-positive-data-results-from
-
ETH-Spin-off plant neues Anti-Corona-Medikament
(Hinzugefügt: 20.06.2021 um 17:45 Uhr)
https://www.20min.ch/story/eth-spin-off-plant-neues-anti-corona-medikament-300119958255
-
Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents
(Hinzugefügt: 20.06.2021 um 17:39 Uhr)
https://www.sciencedirect.com/science/article/pii/S0306987721001419
-
Pfizer Medicine Reduces The Risk of Death from Covid-19 by 37%, Reveals Study Carried Out in Brazil
(Hinzugefügt: 20.06.2021 um 17:23 Uhr)
https://www1.folha.uol.com.br/internacional/en/scienceandhealth/2021/06/pfizer-medicine-reduces-the-risk-of-death-from-covid-19-by-37-reveals-study-carried-out-in-brazil.shtml
-
Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial
(Hinzugefügt: 20.06.2021 um 10:48 Uhr)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00242-X/fulltext
-
COVID-19: JAK-Inhibitor Tofacitinib verbessert Prognose von hospitalisierten Patienten
(Hinzugefügt: 20.06.2021 um 10:46 Uhr)
https://www.aerzteblatt.de/nachrichten/124822/COVID-19-JAK-Inhibitor-Tofacitinib-verbessert-Prognose-von-hospitalisierten-Patienten
-
Senolytics reduce coronavirus-related mortality in old mice
(Hinzugefügt: 20.06.2021 um 10:40 Uhr)
https://science.sciencemag.org/content/early/2021/06/07/science.abe4832.full
-
SARS-CoV-2: Senolytikum erhöht Überlebenschancen in präklinischer Studie
(Hinzugefügt: 09.06.2021 um 19:59 Uhr)
https://www.aerzteblatt.de/nachrichten/124543/SARS-CoV-2-Senolytikum-erhoeht-Ueberlebenschancen-in-praeklinischer-Studie
-
Comment on: “Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry”
(Hinzugefügt: 09.06.2021 um 19:40 Uhr)
https://link.springer.com/article/10.1007/s40265-021-01537-7
-
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
(Hinzugefügt: 09.06.2021 um 19:40 Uhr)
https://www.nature.com/articles/s41586-021-03676-z
-
Could Statins Do More Than Lower Cholesterol in Patients With COVID-19?
(Hinzugefügt: 09.06.2021 um 19:28 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2780872
-
“Nanotraps” Designed to Capture and Clear SARS-CoV-2
(Hinzugefügt: 09.06.2021 um 19:23 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2780639
-
In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis
(Hinzugefügt: 09.06.2021 um 19:15 Uhr)
https://link.springer.com/article/10.1007/s43440-021-00233-3
-
NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure
(Hinzugefügt: 06.06.2021 um 14:58 Uhr)
https://ir.nrxpharma.com/news-events/press-releases/detail/69/nrx-pharmaceuticals-announces-positive-results-for
-
NIH researchers identify potential new antiviral drug for COVID-19
(Hinzugefügt: 06.06.2021 um 14:42 Uhr)
https://www.nih.gov/news-events/news-releases/nih-researchers-identify-potential-new-antiviral-drug-covid-19
-
SARS-CoV-2-Infektion: Lokale Behandlung mit physikalischem Plasma
(Hinzugefügt: 06.06.2021 um 14:38 Uhr)
https://www.heilpraxisnet.de/naturheilpraxis/sars-cov-2-infektion-lokale-behandlung-mit-physikalischem-plasma-20210603540056/
-
Early Anakinra Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor
(Hinzugefügt: 28.05.2021 um 08:46 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.16.21257283v1
-
A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection
(Hinzugefügt: 25.05.2021 um 14:07 Uhr)
https://immunology.sciencemag.org/content/6/59/eabi9002.full
-
Pharmacological activation of STING blocks SARS-CoV-2 infection
(Hinzugefügt: 25.05.2021 um 14:06 Uhr)
https://immunology.sciencemag.org/content/6/59/eabi9007.full
-
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta ag
(Hinzugefügt: 25.05.2021 um 13:50 Uhr)
https://www.synairgen.com/umbraco/Surface/Download/GetFile?cid=8d9f857b-aa75-42d5-b447-6312410ec03c
-
Queensland scientists develop peptide-based drugs that could reduce severity of COVID-19
(Hinzugefügt: 25.05.2021 um 13:47 Uhr)
https://www.abc.net.au/news/2021-05-25/brisbane-covid-drugs-could-reduce-severity-of-covid-19/100162184
-
406-11 - Effects Of Dapagliflozin On Prevention Of Major Clinical Events And Recovery In Patients With Respiratory Failure Due To COVID-19 - Main Results From The DARE-19 Randomized Trial
(Hinzugefügt: 22.05.2021 um 18:10 Uhr)
https://www.abstractsonline.com/pp8/#!/9228/presentation/24018
-
Early use of anakinra reduces risk of mortality for patients with COVID-19 pneumonia, reduces ICU admission and increases likelihood of full recovery
(Hinzugefügt: 22.05.2021 um 17:57 Uhr)
https://news.cision.com/swedish-orphan-biovitrum-ab/r/early-use-of-anakinra-reduces-risk-of-mortality-for-patients-with-covid-19-pneumonia--reduces-icu-ad,c3350835
-
Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro
(Hinzugefügt: 22.05.2021 um 17:48 Uhr)
https://www.sciencedirect.com/science/article/pii/S0166354221000796?via%3Dihub
-
World-first COVID-19 antiviral therapy developed in Brisbane and US targets virus in the body
(Hinzugefügt: 20.05.2021 um 06:42 Uhr)
https://www.abc.net.au/news/2021-05-17/queensland-coronavirus-antiviral-treatment-covid-19/100144370
-
Researchers develop direct-acting antiviral therapy to treat COVID-19
(Hinzugefügt: 20.05.2021 um 06:22 Uhr)
https://news.griffith.edu.au/2021/05/17/researchers-develop-direct-acting-antiviral-to-treat-covid-19/
-
A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19
(Hinzugefügt: 15.05.2021 um 10:00 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.13.21256973v1
-
A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19
(Hinzugefügt: 15.05.2021 um 09:53 Uhr)
https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(21)00256-2
-
Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection
(Hinzugefügt: 15.05.2021 um 09:53 Uhr)
https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(21)00088-7
-
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study
(Hinzugefügt: 13.05.2021 um 17:06 Uhr)
https://www.bmj.com/content/373/bmj.n1038
-
WHO startet Prüfung von drei potenziellen Covid-19-Medikamenten
(Hinzugefügt: 12.05.2021 um 07:42 Uhr)
https://www.spiegel.de/wissenschaft/medizin/corona-who-startet-studien-mit-drei-potenziellen-covid-19-medikamenten-a-cf83e708-3238-4061-8580-b843403b31b6?sara_ecid=soci_upd_KsBF0AFjflf0DZCxpPYDCQgO1dEMph
-
International COVID-19 trial to restart with focus on immune responses
(Hinzugefügt: 12.05.2021 um 07:41 Uhr)
https://www.nature.com/articles/d41586-021-01090-z
-
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study
(Hinzugefügt: 10.05.2021 um 15:48 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00104-1/fulltext
-
Europäische Arzneimittelagentur untersucht neue COVID-19-Therapie
(Hinzugefügt: 08.05.2021 um 12:23 Uhr)
https://www.aerzteblatt.de/nachrichten/123701/Europaeische-Arzneimittelagentur-untersucht-neue-COVID-19-Therapie
-
The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms (COV-PREVENT)
(Hinzugefügt: 07.05.2021 um 06:37 Uhr)
https://www.clinicaltrials.gov/ct2/show/NCT04854759
-
A machine learning platform to estimate anti-SARS-CoV-2 activities
(Hinzugefügt: 07.05.2021 um 06:35 Uhr)
https://www.nature.com/articles/s42256-021-00335-w
-
Human Organ Chips Shift Amodiaquine from Old Antimalarial to Promising COVID-19 Treatment
(Hinzugefügt: 05.05.2021 um 08:14 Uhr)
https://www.genengnews.com/news/human-organ-chips-shift-amodiaquine-from-old-antimalarial-to-promising-covid-19-treatment/
-
A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics
(Hinzugefügt: 04.05.2021 um 05:36 Uhr)
https://www.nature.com/articles/s41551-021-00718-9
-
Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection
(Hinzugefügt: 03.05.2021 um 16:07 Uhr)
https://www.sciencedirect.com/science/article/pii/S0753332221002225
-
Pfizer CEO Says Antiviral Pill To Treat Covid Could Be Ready By The End Of The Year
(Hinzugefügt: 30.04.2021 um 06:07 Uhr)
https://www.forbes.com/sites/tommybeer/2021/04/27/pfizer-ceo-says-antiviral-pill-to-treat-covid-could-be-ready-by-end-of-the-year/?sh=52e2e4262a0d
-
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
(Hinzugefügt: 30.04.2021 um 05:49 Uhr)
https://www.cell.com/structure/fulltext/S0969-2126(21)00121-0
-
Hepatitis C Virus Drugs That Inhibit the SARS-CoV-2 Papain-Like Protease Synergize with Remdesivir to Suppress Viral Replication in Cell Culture
(Hinzugefügt: 30.04.2021 um 05:48 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00472-1
-
Wie vielversprechend ist die Anti-Corona-Pille von Pfizer?
(Hinzugefügt: 30.04.2021 um 05:46 Uhr)
https://www.t-online.de/gesundheit/krankheiten-symptome/id_89921058/wie-vielversprechend-ist-die-anti-corona-pille-von-pfizer-.html
-
Network medicine framework for identifying drug-repurposing opportunities for COVID-19
(Hinzugefügt: 30.04.2021 um 05:38 Uhr)
https://www.pnas.org/content/118/19/e2025581118
-
Nanobodies inhibit SARS-CoV-2 infection, including emergent variants
(Hinzugefügt: 29.04.2021 um 07:34 Uhr)
https://phys.org/news/2021-04-nanobodies-inhibit-sars-cov-infection-emergent.html
-
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial
(Hinzugefügt: 29.04.2021 um 07:17 Uhr)
https://www.researchsquare.com/article/rs-462937/v1
-
Role of Statins in Coronavirus-Related Disease (COVID-19): A Retrospective Cohort Study in Northern Italy
(Hinzugefügt: 29.04.2021 um 07:08 Uhr)
https://link.springer.com/article/10.1007/s40292-021-00452-y
-
Anti-inflammatory potential of Quercetin in COVID-19 treatment
(Hinzugefügt: 25.04.2021 um 09:51 Uhr)
https://journal-inflammation.biomedcentral.com/articles/10.1186/s12950-021-00268-6
-
Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells
(Hinzugefügt: 24.04.2021 um 06:08 Uhr)
https://www.sciencedirect.com/science/article/pii/S0021925821004907
-
Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
(Hinzugefügt: 21.04.2021 um 06:17 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.19.21255441v1
-
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
(Hinzugefügt: 21.04.2021 um 06:17 Uhr)
https://www.frontiersin.org/articles/10.3389/fphar.2021.652688/full
-
Nanotraps for the containment and clearance of SARS-CoV-2
(Hinzugefügt: 21.04.2021 um 05:58 Uhr)
https://www.cell.com/matter/fulltext/S2590-2385(21)00166-1
-
Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19
(Hinzugefügt: 19.04.2021 um 06:41 Uhr)
https://www.rigel.com/investors/news-events/press-releases/detail/312/positive-topline-data-shows-fostamatinib-meets-primary
-
Evaluation of Thiamine as Adjunctive Therapy in COVID-19 Critically Ill Patients: A Multicenter Propensity Score Matched Study
(Hinzugefügt: 15.04.2021 um 06:30 Uhr)
https://www.researchsquare.com/article/rs-400565/v1
-
Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19
(Hinzugefügt: 15.04.2021 um 06:13 Uhr)
https://www.frontiersin.org/articles/10.3389/fmed.2020.614393/full?fbclid=IwAR2xINK_xugxFV6tFR2OkDXgrNkWuAgQ_4BH-s5HeqrCKh1EhRYQdOQ86ck
-
Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2
(Hinzugefügt: 14.04.2021 um 06:57 Uhr)
https://link.springer.com/article/10.1007/s43440-021-00231-5
-
Amantadine Inhibits SARS-CoV-2 In Vitro
(Hinzugefügt: 14.04.2021 um 06:57 Uhr)
https://www.mdpi.com/1999-4915/13/4/539
-
Role of Aviptadil in COVID-19
(Hinzugefügt: 13.04.2021 um 11:09 Uhr)
https://lastfuturist.com/role-of-aviptadil-in-covid-19/
-
MedUni Wien entwickelt Medikament gegen schwere Covid-Verläufe
(Hinzugefügt: 12.04.2021 um 18:00 Uhr)
https://www.vienna.at/meduni-wien-entwickelt-medikament-gegen-schwere-covid-verlaeufe/6955313
-
Two Currently Available Medications – an Antifungal and an Antidepressant – May Help Protect Against COVID-19
(Hinzugefügt: 09.04.2021 um 06:12 Uhr)
https://scitechdaily.com/two-currently-available-medications-an-antifungal-and-an-antidepressant-may-help-protect-against-covid-19/
-
Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia
(Hinzugefügt: 07.04.2021 um 17:32 Uhr)
https://www.nature.com/articles/s41586-021-03491-6
-
Ciclosporin und Pelitinib könnten gegen SARS-CoV-2 wirksam sein
(Hinzugefügt: 07.04.2021 um 07:10 Uhr)
https://www.aerzteblatt.de/nachrichten/122696/Ciclosporin-und-Pelitinib-koennten-gegen-SARS-CoV-2-wirksam-sein
-
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19
(Hinzugefügt: 06.04.2021 um 06:55 Uhr)
https://intranet.grifols.com/documents/38081080/1025666635/np-20210402-en.pdf/2b639903-5415-477a-94f1-0c5938185074
-
Oraler Proteasehemmer gegen Corona geht in klinische Prüfung
(Hinzugefügt: 05.04.2021 um 13:32 Uhr)
https://www.pharmazeutische-zeitung.de/oraler-proteasehemmer-gegen-corona-geht-in-klinische-pruefung-124794/
-
Ascorbic Acid as an Adjunctive Therapy in Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study
(Hinzugefügt: 04.04.2021 um 17:35 Uhr)
https://www.researchsquare.com/article/rs-354711/v1
-
Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including SARS-CoV-2
(Hinzugefügt: 04.04.2021 um 17:22 Uhr)
https://www.mdpi.com/1420-3049/26/6/1775/htm
-
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
(Hinzugefügt: 03.04.2021 um 05:59 Uhr)
https://science.sciencemag.org/content/early/2021/03/31/science.abf7945.full
-
Real-world Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID-19 Patients
(Hinzugefügt: 01.04.2021 um 19:03 Uhr)
https://www.researchsquare.com/article/rs-369927/v1
-
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
(Hinzugefügt: 30.03.2021 um 19:11 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)00382-2
-
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
(Hinzugefügt: 29.03.2021 um 18:24 Uhr)
https://www.prnewswire.com/news-releases/neurorx-announces-zyesami-aviptadil-rlf-100-met-the-primary-endpoint-of-its-phase-2b3-clinical-trial-and-also-demonstrated-a-meaningful-benefit-in-survival-from-critical-covid-19-301257291.html
-
Identification of antiviral antihistamines for COVID-19 repurposing
(Hinzugefügt: 28.03.2021 um 08:55 Uhr)
https://www.sciencedirect.com/science/article/pii/S0006291X20321409
-
Potential anti-COVID-19 agents, Cepharanthine and Nelfinavir, and their usage for combination treatment
(Hinzugefügt: 28.03.2021 um 08:42 Uhr)
https://www.cell.com/iscience/fulltext/S2589-0042(21)00335-7
-
PDF [8 MB] Figures Save Share Reprints Request Potential anti-COVID-19 agents, Cepharanthine and Nelfinavir, and their usage for combination treatment
(Hinzugefügt: 27.03.2021 um 04:03 Uhr)
https://www.cell.com/iscience/fulltext/S2589-0042(21)00335-7
-
Opaganib Krebsmedikament gegen Covid-19 in Erprobung
(Hinzugefügt: 26.03.2021 um 20:54 Uhr)
https://www.pharmazeutische-zeitung.de/krebsmedikament-gegen-covid-19-in-erprobung-117612/
-
Opaganib in Italien im Härtefalleinsatz
(Hinzugefügt: 26.03.2021 um 20:53 Uhr)
https://www.deutsche-apotheker-zeitung.de/news/artikel/2020/04/14/opaganib-in-italien-im-haertefalleinsatz
-
Aspirin könnte Corona-Infektionsrisiko laut Studie „signifikant“ reduzieren
(Hinzugefügt: 26.03.2021 um 20:34 Uhr)
https://www.fr.de/wissen/corona-virus-aspirin-ass-infektion-risiko-ansteckung-covid-studie-israel-90258238.html
-
Rapid Clinical Recovery from Critical COVID-19 Pneumonia with Vasoactive Intestinal Peptide Treatment
(Hinzugefügt: 25.03.2021 um 20:21 Uhr)
https://www.sciencedirect.com/science/article/pii/S1053249821020702
-
Does the secret to an effective COVID-19 treatment lie in a protease inhibitor?
(Hinzugefügt: 24.03.2021 um 09:10 Uhr)
https://www.pfizer.com/science/coronavirus/antiviral-efforts
-
Neutrons reveal unpredicted binding between SARS-CoV-2, hepatitis C antiviral drug
(Hinzugefügt: 24.03.2021 um 09:06 Uhr)
https://www.ornl.gov/news/neutrons-reveal-unpredicted-binding-between-sars-cov-2-hepatitis-c-antiviral-drug
-
Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro
(Hinzugefügt: 24.03.2021 um 08:53 Uhr)
https://www.biorxiv.org/content/10.1101/2021.03.22.436379v1
-
Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia
(Hinzugefügt: 22.03.2021 um 07:37 Uhr)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239692
-
In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2
(Hinzugefügt: 19.03.2021 um 08:34 Uhr)
https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(21)00043-7
-
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
(Hinzugefügt: 18.03.2021 um 06:05 Uhr)
https://www.nature.com/articles/s41586-021-03431-4
-
BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection
(Hinzugefügt: 17.03.2021 um 01:47 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)00354-8
-
Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro
(Hinzugefügt: 14.03.2021 um 05:41 Uhr)
https://www.cell.com/heliyon/fulltext/S2405-8440(21)00531-4
-
Androgen Receptors for COVID-19
(Hinzugefügt: 13.03.2021 um 07:48 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2021/03/11/androgen-receptors-for-covid-19
-
Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients
(Hinzugefügt: 13.03.2021 um 07:33 Uhr)
https://en.kintor.com.cn/news/166.html
-
Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients
(Hinzugefügt: 11.03.2021 um 14:34 Uhr)
https://www.biospace.com/article/releases/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-percent-reduction-in-mortality-in-hospitalized-covid-19-patients/
-
ANN KOMMT AT-527?: Das wissen wir bereits über die Anti-Corona-Pille von Roche
(Hinzugefügt: 10.03.2021 um 08:19 Uhr)
https://www.20min.ch/story/das-wissen-wir-bereits-ueber-die-anti-corona-pille-von-roche-980401234590
-
Seeking to combat COVID-19 with an oral RNA viral polymerase inhibitor.
(Hinzugefügt: 10.03.2021 um 08:19 Uhr)
https://ateapharma.com/at-527/
-
Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – A retrospective observational study in elderly patients
(Hinzugefügt: 10.03.2021 um 08:11 Uhr)
https://www.sciencedirect.com/science/article/pii/S1094553921000018
-
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
(Hinzugefügt: 07.03.2021 um 08:20 Uhr)
https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/
-
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
(Hinzugefügt: 06.03.2021 um 08:23 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00461-X/fulltext
-
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
(Hinzugefügt: 04.03.2021 um 15:25 Uhr)
https://www.sciencedirect.com/science/article/pii/S2352396421000487
-
Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19
(Hinzugefügt: 04.03.2021 um 08:09 Uhr)
https://www.sciencedirect.com/science/article/pii/S200103702100060X
-
The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing
(Hinzugefügt: 04.03.2021 um 07:56 Uhr)
https://www.cell.com/heliyon/fulltext/S2405-8440(21)00492-8
-
Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19
(Hinzugefügt: 03.03.2021 um 08:37 Uhr)
https://www.sciencedirect.com/science/article/pii/S2589004221002224
-
Studie identifiziert mögliche Hemmstoffe von SARS-CoV-2
(Hinzugefügt: 02.03.2021 um 06:55 Uhr)
https://www.aerzteblatt.de/nachrichten/121628/Studie-identifiziert-moegliche-Hemmstoffe-von-SARS-CoV-2
-
Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine
(Hinzugefügt: 02.03.2021 um 06:49 Uhr)
https://pubs.acs.org/doi/10.1021/acschemneuro.1c00019
-
Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
(Hinzugefügt: 28.02.2021 um 07:40 Uhr)
http://www.ipharminc.com/press-release/2021/2/26/innovation-pharma-provides-study-details-for-ongoing-phase-2-clinical-trial-of-brilacidin-in-hospitalized-covid-19-patients
-
A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review
(Hinzugefügt: 28.02.2021 um 07:40 Uhr)
https://www.frontiersin.org/articles/10.3389/fphar.2020.590154/full
-
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
(Hinzugefügt: 26.02.2021 um 18:30 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2023184
-
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
(Hinzugefügt: 26.02.2021 um 18:29 Uhr)
https://www.globenewswire.com/news-release/2021/02/26/2183438/0/en/Revive-Therapeutics-Provides-Update-on-FDA-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19-with-Planned-Completion-and-Emergency-Use-Authorization-Request.html
-
Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study
(Hinzugefügt: 26.02.2021 um 03:45 Uhr)
https://www.nature.com/articles/s41380-021-01021-4
-
INDEPENDENT DATA MONITORING COMMITTEE FINDS CLEAR EFFICACY FOR REGEN-COV™ (CASIRIVIMAB WITH IMDEVIMAB) IN PHASE 3 COVID-19 OUTPATIENT OUTCOMES TRIAL
(Hinzugefügt: 26.02.2021 um 03:43 Uhr)
https://investor.regeneron.com/news-releases/news-release-details/independent-data-monitoring-committee-finds-clear-efficacy-regen/
-
Israeli researchers say spirulina algae could reduce COVID mortality rate
(Hinzugefügt: 26.02.2021 um 03:29 Uhr)
https://www.jpost.com/health-science/israeli-researchers-say-spirulina-algae-could-stop-covid-19-deaths-660064
-
Could fluvoxamine keep COVID19 patients out of hospitals and intensive care units?
(Hinzugefügt: 26.02.2021 um 03:24 Uhr)
http://neuron.mefst.hr/docs/CMJ/issues/2021/62/1/Ahead%20of%20print/cmj_62_1_aop01.pdf
-
SARS-CoV-2 dependence on host pathways
(Hinzugefügt: 26.02.2021 um 03:11 Uhr)
https://science.sciencemag.org/content/371/6532/884.full
-
Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
(Hinzugefügt: 24.02.2021 um 08:53 Uhr)
https://www.cureus.com/articles/52299-proxalutamide-significantly-accelerates-viral-clearance-and-reduces-time-to-clinical-remission-in-patients-with-mild-to-moderate-covid-19-results-from-a-randomized-double-blinded-placebo-controlled-trial
-
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint
(Hinzugefügt: 24.02.2021 um 08:44 Uhr)
https://www.prnewswire.com/news-releases/neurorx-announces-that-zyesami-aviptadil-has-successfully-demonstrated-10-day-accelerated-recovery-from-respiratory-failure-in-critically-ill-patients-with-covid-19-treated-with-high-flow-nasal-oxygen-at-28-day-inte
-
Sulodexide in the Treatment of Early Stages of COVID-19
(Hinzugefügt: 20.02.2021 um 12:17 Uhr)
https://www.sciencedirect.com/science/article/pii/S2213333X20306673
-
Bepridil is potent against SARS-CoV-2 in vitro
(Hinzugefügt: 20.02.2021 um 12:13 Uhr)
https://www.pnas.org/content/118/10/e2012201118
-
SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
(Hinzugefügt: 19.02.2021 um 09:57 Uhr)
https://science.sciencemag.org/content/early/2021/02/17/science.abf1611.full
-
Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
(Hinzugefügt: 18.02.2021 um 20:31 Uhr)
https://www.nature.com/articles/s41467-021-21310-4
-
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
(Hinzugefügt: 18.02.2021 um 13:33 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33561864/
-
ACTIV Update: Making Major Strides in COVID-19 Therapeutic Development
(Hinzugefügt: 17.02.2021 um 03:25 Uhr)
https://directorsblog.nih.gov/2021/02/16/activ-update-making-major-strides-in-covid-19-therapeutic-development/
-
Groundbreaking COVID-19 treatments to be fast-tracked through clinical trials
(Hinzugefügt: 16.02.2021 um 11:47 Uhr)
https://www.gov.uk/government/news/groundbreaking-covid-19-treatments-to-be-fast-tracked-through-clinical-trials
-
Can glycine mitigate COVID-19 associated tissue damage and cytokine storm ?
(Hinzugefügt: 13.02.2021 um 13:27 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574884/
-
Four potential COVID-19 therapeutics enter Phase 2/3 testing in NIH ACTIV-2 trial
(Hinzugefügt: 13.02.2021 um 13:25 Uhr)
https://www.nih.gov/news-events/news-releases/four-potential-covid-19-therapeutics-enter-phase-2-3-testing-nih-activ-2-trial
-
Asthmaspray mit Budesonid verhindert schwere Verläufe
(Hinzugefügt: 12.02.2021 um 08:25 Uhr)
https://www.aerzteblatt.de/nachrichten/121073/SARS-CoV-2-Asthmaspray-mit-Budesonid-verhindert-schwere-Verlaeufe
-
Proxalutamide (GT0918) Reduces the Rate of Hospitalization and Death in COVID-19 Male Patients: A Randomized Double-Blinded Placebo-Controlled Trial.
(Hinzugefügt: 12.02.2021 um 08:16 Uhr)
https://www.researchsquare.com/article/rs-135303/v1
-
NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19
(Hinzugefügt: 10.02.2021 um 09:52 Uhr)
https://www.neurorxpharma.com/press-releases/neurorx-and-relief-therapeutics-report-initial-phase-2b-3-study-results-demonstrating-significant-benefit-of-zyesami-in-reducing-hospital-stay-among-patients-with-respiratory-failure-due-to-c/
-
In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs
(Hinzugefügt: 10.02.2021 um 09:38 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)00158-6?rss=yes
-
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
(Hinzugefügt: 10.02.2021 um 09:36 Uhr)
https://www.nature.com/articles/s41586-021-03312-w
-
Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests
(Hinzugefügt: 09.02.2021 um 09:19 Uhr)
https://oxfordbrc.nihr.ac.uk/common-asthma-treatment-reduces-need-for-hospitalisation-in-covid-19-patients-study-suggests/
-
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
(Hinzugefügt: 07.02.2021 um 10:10 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30566-X/fulltext
-
New Israeli drug cured 29 of 30 moderate/serious COVID cases in days — hospital
(Hinzugefügt: 06.02.2021 um 09:34 Uhr)
https://www.timesofisrael.com/new-israeli-drug-cured-moderate-to-serious-covid-cases-within-days-hospital/
-
Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus
(Hinzugefügt: 04.02.2021 um 09:15 Uhr)
https://www.mdpi.com/1999-4915/13/2/234
-
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
(Hinzugefügt: 04.02.2021 um 09:08 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00149-5/fulltext
-
Prospective cohort of fluvoxamine for early treatment of COVID-19
(Hinzugefügt: 02.02.2021 um 10:00 Uhr)
https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab050/6124100
-
17β‐estradiol reduces SARS‐CoV‐2 infection in vitro
(Hinzugefügt: 31.01.2021 um 10:15 Uhr)
https://physoc.onlinelibrary.wiley.com/doi/10.14814/phy2.14707
-
plitidepsin (Aplidin), a drug approved by the Australian Regulatory Agency for the treatment of multiple myeloma, has potent antiviral activity against SARS-CoV-2
(Hinzugefügt: 28.01.2021 um 09:21 Uhr)
https://www.ucsf.edu/news/2021/01/419686/cancer-drug-shows-potent-activity-lab-against-sars-cov-2-including-b117-variant
-
Coronavirus replication–transcription complex: Vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit
(Hinzugefügt: 26.01.2021 um 10:21 Uhr)
https://www.pnas.org/content/118/6/e2022310118
-
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
(Hinzugefügt: 26.01.2021 um 09:08 Uhr)
https://science.sciencemag.org/content/early/2021/01/22/science.abf4058.full
-
Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant
(Hinzugefügt: 26.01.2021 um 09:08 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.24.427991v1
-
Woran die Pharmabranche forscht Schwierige Suche nach Covid-Medikamenten
(Hinzugefügt: 25.01.2021 um 12:48 Uhr)
https://www.tagesschau.de/wirtschaft/corona-medikament-101.html
-
Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy
(Hinzugefügt: 24.01.2021 um 18:31 Uhr)
https://www.sciencedirect.com/science/article/pii/S0306987720333673
-
N-Acetylcysteine to Combat COVID-19: An Evidence Review
(Hinzugefügt: 24.01.2021 um 18:26 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649937/
-
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
(Hinzugefügt: 22.01.2021 um 21:44 Uhr)
https://www.nature.com/articles/s42003-020-01577-x
-
α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action
(Hinzugefügt: 22.01.2021 um 09:25 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00018-7/fulltext
-
GABA administration prevents severe illness and death following coronavirus infection in mice
(Hinzugefügt: 20.01.2021 um 09:04 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536896/pdf/nihpp-2020.10.04.325423.pdf
-
COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection
(Hinzugefügt: 18.01.2021 um 07:15 Uhr)
https://www.mdpi.com/1424-8247/14/1/71
-
Artemisia annua L. extracts prevent in vitro replication of SARS-CoV-2
(Hinzugefügt: 13.01.2021 um 08:24 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.08.425825v1
-
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
(Hinzugefügt: 13.01.2021 um 08:01 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.05.21249237v1
-
The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models
(Hinzugefügt: 12.01.2021 um 20:36 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.10.426114v1
-
Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
(Hinzugefügt: 11.01.2021 um 08:15 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.08.20248149v1
-
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
(Hinzugefügt: 10.01.2021 um 09:15 Uhr)
https://link.springer.com/article/10.1007/s00406-020-01231-x
-
Impact of colchicine on mortality in patients with COVID-19. A meta-analysis.
(Hinzugefügt: 08.01.2021 um 10:18 Uhr)
https://www.sciencedirect.com/science/article/pii/S1109966620302852
-
Quercetin: Antiviral Significance and Possible COVID-19 Integrative Considerations
(Hinzugefügt: 08.01.2021 um 09:44 Uhr)
https://journals.sagepub.com/doi/full/10.1177/1934578X20976293
-
Existing antihistamine drugs show effectiveness against COVID-19 virus in cell testing
(Hinzugefügt: 07.01.2021 um 05:27 Uhr)
https://m.ufhealth.org/news/2020/existing-antihistamine-drugs-show-effectiveness-against-covid-19-virus-cell-testing
-
FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2
(Hinzugefügt: 06.01.2021 um 08:42 Uhr)
https://academic.oup.com/bioinformatics/article/36/Supplement_2/i813/6055936
-
Guanylatkinase (GK1) SARS-CoV-2: Bioinformatiker entdecken eine neue Schwachstelle des Virus
(Hinzugefügt: 06.01.2021 um 08:41 Uhr)
https://www.dzif.de/de/sars-cov-2-bioinformatiker-entdecken-eine-neue-schwachstelle-des-virus-0
-
Umbilical stem cells show promise against severe COVID-19
(Hinzugefügt: 06.01.2021 um 08:36 Uhr)
https://www.upi.com/Health_News/2021/01/05/Umbilical-stem-cells-show-promise-against-severe-COVID-19/1611609873569/
-
CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy
(Hinzugefügt: 06.01.2021 um 08:26 Uhr)
https://link.springer.com/article/10.1007/s11030-020-10169-0
-
Umbilical cord mesenchymal stem cells for COVID‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial
(Hinzugefügt: 06.01.2021 um 08:25 Uhr)
https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.20-0472
-
Amantadin has potential for the treatment of COVID-19 because it targets known and novel ion channels encoded by SARS-CoV-2
(Hinzugefügt: 05.01.2021 um 08:17 Uhr)
https://www.researchsquare.com/article/rs-121743/v1
-
SARS-CoV-2: ACE-Hemmer könnten Risiko auf schweren Krankheitsverlauf senken
(Hinzugefügt: 05.01.2021 um 08:06 Uhr)
https://www.aerzteblatt.de/nachrichten/119841/SARS-CoV-2-ACE-Hemmer-koennten-Risiko-auf-schweren-Krankheitsverlauf-senken
-
Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: an in silico approach
(Hinzugefügt: 04.01.2021 um 18:55 Uhr)
https://www.sciencedirect.com/science/article/pii/S2225411021000018
-
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
(Hinzugefügt: 03.01.2021 um 20:00 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2773108?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=010321#.X_F_xDqfFcE
-
Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico / in vitro assessment
(Hinzugefügt: 03.01.2021 um 19:57 Uhr)
https://www.sciencedirect.com/science/article/abs/pii/S0022286020321815
-
Large population study identifies drugs associated with reduced COVID-19 severity
(Hinzugefügt: 01.01.2021 um 19:20 Uhr)
https://www.medrxiv.org/content/10.1101/2020.10.13.20211953v2
-
Higher Survival Rate Associated with Thymosin Alpha 1 use in Critical COVID-19: A Retrospective Multicenter Cohort Study
(Hinzugefügt: 30.12.2020 um 08:06 Uhr)
https://www.researchsquare.com/article/rs-123265/v1
-
SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement?
(Hinzugefügt: 30.12.2020 um 08:05 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33298888/
-
Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir
(Hinzugefügt: 30.12.2020 um 07:57 Uhr)
https://www.sciencedirect.com/science/article/pii/S1876034120307735
-
Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19
(Hinzugefügt: 29.12.2020 um 09:39 Uhr)
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(20)30679-X
-
Bosnian company produces drug that accelerates COVID-19 recovery process
(Hinzugefügt: 26.12.2020 um 10:01 Uhr)
http://ba.n1info.com/English/NEWS/a498471/Bosnian-company-produces-drug-that-accelerates-COVID-19-recovery-process.html
-
Human SARS-CoV-2 neutralizing antibody COR-101 demonstrates high efficacy in a COVID-19 animal model and is ready to be used in clinical studies to treat COVID-19 patients
(Hinzugefügt: 22.12.2020 um 07:24 Uhr)
http://corat-therapeutics.com/wp-content/uploads/2020/12/PR_2020.12.04_CORAT_COR-101-demonstrates-high-efficacy-in-a-COVID-19-animal-model.pdf
-
Can Activation of NRF2 Be a Strategy against COVID-19?
(Hinzugefügt: 19.12.2020 um 12:06 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359808/
-
Synairgen plc SNG001 given Fast Track designation and IND cleared by the US FDA
(Hinzugefügt: 18.12.2020 um 21:44 Uhr)
https://www.globenewswire.com/news-release/2020/12/18/2147530/0/en/COVID-19-Clinical-Programme-Update.html
-
Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections
(Hinzugefügt: 18.12.2020 um 10:37 Uhr)
https://www.sciencedirect.com/science/article/pii/S0944711320302713
-
Foistar(Camostat mesylate) associated with the significant decrease in CRP levels compared to Kaletra(Lopinavir/Ritonavir) treatment in Korean mild COVID-19 pneumonic patients.
(Hinzugefügt: 17.12.2020 um 08:35 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.10.20240689v1
-
Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
(Hinzugefügt: 16.12.2020 um 18:51 Uhr)
https://www.pnas.org/content/117/50/32105
-
Aprotinin Inhibits SARS-CoV-2 Replication
(Hinzugefügt: 16.12.2020 um 08:06 Uhr)
https://www.mdpi.com/2073-4409/9/11/2377
-
Thalidomide Combined with Short-term Low-Dose Glucocorticoid Therapy for the Treatment of Severe COVID-19: A Case-Series Study
(Hinzugefügt: 15.12.2020 um 19:01 Uhr)
https://www.sciencedirect.com/science/article/pii/S1201971220325467
-
Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV-2 Replication in Cell Culture
(Hinzugefügt: 15.12.2020 um 19:01 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.13.422511v1
-
A retrospective comparison of drugs against COVID-19
(Hinzugefügt: 15.12.2020 um 09:54 Uhr)
https://www.sciencedirect.com/science/article/abs/pii/S0168170220311692
-
RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19
(Hinzugefügt: 14.12.2020 um 18:37 Uhr)
https://www.recoverytrial.net/news/recovery-trial-finds-no-benefit-from-azithromycin-in-patients-hospitalised-with-covid-19
-
Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
(Hinzugefügt: 14.12.2020 um 07:17 Uhr)
https://lib.ossn.ru/jour/article/view/1440/
-
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
(Hinzugefügt: 13.12.2020 um 15:25 Uhr)
https://www.nature.com/articles/s41564-020-00835-2
-
Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b–Literature Review and Personal Preliminary Experience
(Hinzugefügt: 13.12.2020 um 10:40 Uhr)
https://www.frontiersin.org/articles/10.3389/fphar.2020.592543/full
-
Sulodexide in the treatment of patients with early stages of COVID-19: a randomised controlled trial
(Hinzugefügt: 09.12.2020 um 18:44 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.04.20242073v1
-
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019
(Hinzugefügt: 09.12.2020 um 18:41 Uhr)
https://journal.chestnet.org/article/S0012-3692(20)34898-4/fulltext
-
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis
(Hinzugefügt: 09.12.2020 um 09:08 Uhr)
https://www.sciencedirect.com/science/article/pii/S2666756820300337?via%3Dihub#!
-
Molnupiravir (4482/EIDD-2801) Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
(Hinzugefügt: 09.12.2020 um 09:07 Uhr)
https://www.nature.com/articles/s41564-020-00835-2
-
COVID-19: Metformin könnte Sterberisiko bei Frauen mit Typ-2-Diabetes senken
(Hinzugefügt: 09.12.2020 um 00:33 Uhr)
https://www.aerzteblatt.de/nachrichten/119145/COVID-19-Metformin-koennte-Sterberisiko-bei-Frauen-mit-Typ-2-Diabetes-senken
-
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial
(Hinzugefügt: 08.12.2020 um 08:58 Uhr)
https://www.researchsquare.com/article/rs-116547/v1
-
Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease. A pilot study
(Hinzugefügt: 07.12.2020 um 16:48 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33274479/
-
Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19
(Hinzugefügt: 06.12.2020 um 17:08 Uhr)
https://pubs.acs.org/doi/10.1021/acsptsci.0c00179
-
Efficacy and Safety of Topical Ivermectin + IotaCarrageenan in the Prophylaxis against COVID-19 in Health Personnel
(Hinzugefügt: 06.12.2020 um 16:59 Uhr)
https://medicalpressopenaccess.com/upload/1605709669_1007.pdf
-
Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals
(Hinzugefügt: 06.12.2020 um 16:55 Uhr)
https://www.cell.com/structure/fulltext/S0969-2126(20)30379-8?_r
-
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis
(Hinzugefügt: 05.12.2020 um 08:30 Uhr)
https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(20)30033-7/fulltext
-
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
(Hinzugefügt: 04.12.2020 um 09:26 Uhr)
https://clinicaltrials.gov/ct2/show/NCT04575584
-
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms
(Hinzugefügt: 03.12.2020 um 18:22 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.01.407361v1
-
A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
(Hinzugefügt: 03.12.2020 um 18:20 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.01.20239574v1
-
A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
(Hinzugefügt: 03.12.2020 um 12:29 Uhr)
https://www.sciencedirect.com/science/article/pii/S1201971220325066
-
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia
(Hinzugefügt: 01.12.2020 um 08:06 Uhr)
https://www.nature.com/articles/s41375-020-01087-z
-
Ivermectin: Latin America’s embrace of an unproven COVID treatment is hindering drug trials
(Hinzugefügt: 29.11.2020 um 13:06 Uhr)
https://www.nature.com/articles/d41586-020-02958-2
-
Ivermectin: Latin America’s embrace of an unproven COVID treatment is hindering drug trials
(Hinzugefügt: 29.11.2020 um 13:06 Uhr)
https://www.nature.com/articles/d41586-020-02958-2
-
A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin
(Hinzugefügt: 29.11.2020 um 13:05 Uhr)
https://www.sciencedirect.com/science/article/pii/S0924857920304684
-
VIP in the Treatment of Critical COVID-19 With Respiratory Failure in Patients With Severe Comorbidity: A Prospective Externally-Controlled Trial
(Hinzugefügt: 28.11.2020 um 12:46 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
-
Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2)
(Hinzugefügt: 27.11.2020 um 21:54 Uhr)
https://www.sciencedirect.com/science/article/abs/pii/S0014299920308517
-
Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial
(Hinzugefügt: 27.11.2020 um 21:53 Uhr)
https://www.sciencedirect.com/science/article/pii/S120197122032453X
-
Leronlimab
(Hinzugefügt: 27.11.2020 um 21:48 Uhr)
https://www.globenewswire.com/news-release/2020/11/23/2131590/0/en/CytoDyn-Reaches-Enrollment-Target-of-293-Patients-for-2nd-DSMC-Interim-Analysis-of-Phase-3-COVID-19-Trial-and-Expects-to-Enroll-the-Remaining-97-Patients-in-the-Next-Few-Weeks-to-C.html
-
Colchicine to be investigated as a possible treatment for COVID-19 in the RECOVERY trial
(Hinzugefügt: 27.11.2020 um 21:46 Uhr)
https://www.recoverytrial.net/news/colchicine-to-be-investigated-as-a-possible-treatment-for-covid-19-in-the-recovery-trial
-
Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?
(Hinzugefügt: 26.11.2020 um 08:49 Uhr)
https://meridian.allenpress.com/radiation-research/article/194/5/452/445871/Low-Dose-Radiation-Therapy-LDRT-for-COVID-19
-
baricitinib/ dexamethasone
(Hinzugefügt: 26.11.2020 um 08:48 Uhr)
https://www.nih.gov/news-events/news-releases/fourth-iteration-covid-19-treatment-trial-underway
-
(AVIPTADIL) IN PATIENTS WITH CRITICAL COVID-19 AND SEVERE COMORBIDITY: 72% SURVIVAL SEEN IN ICU PATIENTS
(Hinzugefügt: 24.11.2020 um 20:44 Uhr)
https://relieftherapeutics.com/newsblog/neurorx-and-relief-announce-initial-successful-results-from-expanded-access-use-of-rlf-100-aviptadil-in-patients-with-critical-covid-19-and-severe-comorbidity-72-survival-seen-in-icu-patients
-
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
(Hinzugefügt: 24.11.2020 um 09:13 Uhr)
https://www.medrxiv.org/content/10.1101/2020.11.18.20234161v1
-
Nitazoxanide for Repurposing in COVID-19
(Hinzugefügt: 22.11.2020 um 09:40 Uhr)
https://www.sciencedirect.com/science/article/pii/S0014299920308402
-
Tocilizumab effective in treating sickest COVID-19 patients
(Hinzugefügt: 20.11.2020 um 09:02 Uhr)
https://www.recover-europe.eu/tocilizumab-effective-in-treating-sickest-covid-19-patients/
-
Roche's Actemra helps the sickest COVID-19 patients
(Hinzugefügt: 20.11.2020 um 08:24 Uhr)
https://www.reuters.com/article/us-roche-actemra-trial-idUSKBN27Z1WR
-
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
(Hinzugefügt: 19.11.2020 um 08:05 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(20)30189-0
-
Synergistic Effect of Quercetin and Vitamin C Against COVID-19
(Hinzugefügt: 18.11.2020 um 09:44 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3682517
-
Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19
(Hinzugefügt: 18.11.2020 um 09:13 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459257/
-
Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy
(Hinzugefügt: 18.11.2020 um 09:10 Uhr)
https://www.sciencedirect.com/science/article/pii/S1201971220324589
-
Ivermectin and Doxycycline
(Hinzugefügt: 17.11.2020 um 08:53 Uhr)
http://iaimjournal.com/wp-content/uploads/2020/10/iaim_2020_0710_23.pdf
-
Interferon-b trial shows positive results
(Hinzugefügt: 17.11.2020 um 08:43 Uhr)
https://oxfordbrc.nihr.ac.uk/interferon-b-trial-shows-positive-results/
-
Hinweise, dass eine frühe Therapie mit Interferon-beta-1a-Inhalation oder Fluvoxamin helfen könnte
(Hinzugefügt: 17.11.2020 um 08:42 Uhr)
https://www.aerztezeitung.de/Nachrichten/Hinweise-auf-Arzneien-fuer-fruehe-Therapie-414665.html
-
liposome-based curcumin: lipocurc to restore and boost brain health in COVID-19 syndrome
(Hinzugefügt: 16.11.2020 um 12:26 Uhr)
https://www.sciencedirect.com/science/article/pii/B9780128205938000185
-
Use of Ivermectin in the Prophylaxis and Treatment of COVID-19
(Hinzugefügt: 15.11.2020 um 09:11 Uhr)
https://osf.io/wx3zn/
-
Efficacy and Safety of Ivermectin for Treatment and prophylaxis
(Hinzugefügt: 14.11.2020 um 19:21 Uhr)
https://www.researchsquare.com/article/rs-100956/v1
-
NIHR-supported phase 3 trial of nebulised interferon beta
(Hinzugefügt: 14.11.2020 um 10:56 Uhr)
https://www.nihr.ac.uk/news/covid-19-treatment-results-published-in-journal-ahead-of-nihr-supported-phase-3-trial-of-nebulised-interferon-beta/26186
-
Antidepressivum Fluvoxamin
(Hinzugefügt: 14.11.2020 um 10:42 Uhr)
https://www.aerzteblatt.de/nachrichten/118369/SARS-CoV-2-Kann-ein-Antidepressivum-den-Verlauf-der-Erkrankung-abschwaechen
-
Nebulised interferon beta-1a for patients with COVID-19
(Hinzugefügt: 13.11.2020 um 08:46 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30523-3/fulltext
-
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001)
(Hinzugefügt: 13.11.2020 um 08:36 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
-
Fluvoxamine vs Placebo and Clinical Deterioration
(Hinzugefügt: 13.11.2020 um 08:20 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2773108
-
is there a role for bromhexine as add-on therapy?
(Hinzugefügt: 12.11.2020 um 17:43 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249615/
-
COVID-19 Patients Receiving Compassionate Use Leronlimab
(Hinzugefügt: 12.11.2020 um 08:10 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1583/5932277
-
High-Dose Ivermectin in Adults
(Hinzugefügt: 12.11.2020 um 08:04 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649
-
Alkaloide
(Hinzugefügt: 10.11.2020 um 07:47 Uhr)
https://www.sciencedirect.com/science/article/pii/S0009279720316756
-
PPI / Magenschutz
(Hinzugefügt: 09.11.2020 um 07:08 Uhr)
https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13183
-
Artemisinin-Piperaquine
(Hinzugefügt: 08.11.2020 um 11:54 Uhr)
https://www.sciencedirect.com/science/article/pii/S0924857920304271
-
ACE2 (hrsACE2)
(Hinzugefügt: 06.11.2020 um 07:57 Uhr)
https://www.nature.com/articles/s41392-020-00374-6/
-
Intranasal fusion inhibitory lipopeptide
(Hinzugefügt: 05.11.2020 um 12:29 Uhr)
https://www.biorxiv.org/content/10.1101/2020.11.04.361154v1
-
Ivermectin
(Hinzugefügt: 05.11.2020 um 12:29 Uhr)
https://www.trialsitenews.com/real-world-evidence-i-mask-protocol-ivermectin-key-for-prophylaxis-and-early-treatment-of-covid-19/
-
Interferon
(Hinzugefügt: 05.11.2020 um 08:00 Uhr)
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB
-
synthetic nanobody
(Hinzugefügt: 05.11.2020 um 07:32 Uhr)
https://www.biorxiv.org/content/10.1101/2020.08.08.238469v2
-
Aprotinin Inhibits SARS-CoV-2 Replication
(Hinzugefügt: 05.11.2020 um 07:22 Uhr)
https://www.mdpi.com/2073-4409/9/11/2377
-
Colchicine
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.hindawi.com/journals/cjidmm/2020/8865954/
-
Azelastin
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.biorxiv.org/content/10.1101/2020.09.15.296228v1
-
cetirizine - famotidine
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedirect.com/science/article/pii/S1094553920301462
-
Prozac
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1829082
-
Nicotin
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3677428
-
Prozac
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.n-tv.de/wissen/Prozac-wirkt-gegen-Covid-19-article22120075.html
-
Candesartan
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedirect.com/science/article/pii/S0753332220308465
-
Statine
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedaily.com/releases/2020/09/200923164603.htm
-
EIDD-2801
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.researchsquare.com/article/rs-80404/v1
-
Doxycyclin
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419149/
-
Cyclosporin
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedirect.com/science/article/pii/S2589537020303357
-
Favipiravir
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.trialsitenews.com/fujifilm-toyama-chemical-co-submits-application-for-avigan-favipiravir-approval-for-covid-19-to-japans-health-authority/
-
Famotidin
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.medrxiv.org/content/10.1101/2020.09.28.20203463v1
-
getestete Medikamente
(Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.frontiersin.org/articles/10.3389/fmed.2020.552991/full